Bevacizumab, Lonsurf, Taiho Oncology, tipiracil, Trifluridine
Trifluridine and tipiracil with bevacizumab is approved by FDA for previously treated metastatic colorectal cancer
August 2023: For metastatic colorectal cancer (mCRC) that has already been treated with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy..
FDA, Lonsurf, TAGS (NCT02500043), tipiracil tablets, Trifluridine
Lonsurf is approved by FDA for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma
Trifluridine/tipiracil tablets (LONSURF, Taiho Pharmaceutical Co., Ltd.) were approved by the Food and Drug Administration on February 22, 2019 for adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocar..